Tailored Non-ionic Surfactant Vesicles of Cyclosporine for the Treatment of Psoriasis: Formulation, Ex-Vivo and In-Vivo Investigation-Application of Box-Behnken Design
Peeyush Bhardwaj （ Department of Pharmacy, Bundelkhand University, Jhansi, U.P. 284128, India. ）
Purnima Tripathi （ B.S. Anangpuria Institute of Pharmacy, Alampur, Ballabgarh - Sohna Major District Road, Faridabad, 121004, Haryana, India. ）
Sonia Pandey （ Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Kanpur, U.P. 209217, India. ）
Deepti Chaurasia （ Nkbr College of Pharmacy And Research Centre, Meerut, U.P. 245206, India. ）
Purushottam Ramchandra Patil （ Government College of Pharmacy, Osmanpura, Aurangabad, Maharashtra, India. ）
https://doi.org/10.37155/2717-526X-0502-2Abstract
Psoriasis is an autoimmune skin disease characterized by hyperproliferation of keratinocytes. Topical delivery of drugs is mostly favored for the treatment of mild psoriatic conditions. But permeation of drugs across psoriatic skin is too complex. Niosomes are the non-ionic surfactant vesicles, reported to enhance dermal drug delivery. In the present work, cyclosporine niosomes were, formulated, optimized, and evaluated in-vitro to boost the dermal penetration of cyclosporine for the better management of psoriasis. Niosomes were developed using the thin film hydration method. Formulated niosomes were characterized and optimized for their percent encapsulation efficiency, size, and polydispersity index using Box-Behnken design. Optimized formulation was developed using cholesterol and span 60 (1:2.2), 30 minutes of hydration time, and 30 mg of cyclosporine. Niosomes’ size, polydispersity index, and percent encapsulation efficiency were in the scale of 180.5 ± 11.16 nm, 0.156, and 93.2% ± 2.5%, respectively. The ex-vivo studies were carried out using excised goat skin. In the ex-vivo permeation experiments, though the percent drug permeated was low but the quantity of drug permeated across the skin from the niosomes was significantly greater than from suspension. Skin deposition studies revealed deeper and more significant accumulation of cyclosporine niosomes than the free cyclosporine in the epidermis. The in-vivo experiments were carried out using imiquimod induced psoriatic mice, where both the histopathology and psoriasis area severity index displayed significant recovery in the skin condition of mice treated with niosomes of cyclosporine, in comparison with the dispersion of the drug. The results indicate that the non-ionic surfactant vesicles of cyclosporine can be employed for the enhanced management of psoriasis and reduction of side effects linked with the systemic delivery of cyclosporine.
Keywords
Cyclosporine; Niosomes; Dermal delivery; Box-Behnken design; Psoriasis; OptimizationFull Text
PDFReferences
[2] Christophers E. Psoriasis-epidemiology and clinical spectrum. Clinical and Experimental Dermatology, 2001;26(4):314-320. https://doi.org/10.1046/j.1365-2230.2001.00832.x
[3] Nestle FO, Kaplan DH and Barker J. Mechanisms of disease: psoriasis. New England Journal of Medicine, 2009;361(5):496-509.
[4] Wolf M and Shnyra A. Autoimmune mechanisms of psoriasis: pathogenic role of the IL-23/IL-17 axis. J Autoimmune Disord, 2018;4(1):5. https://doi.org/10.21767/2471-8513.100057
[5] Greaves MW and Weinstein GD. Treatment of psoriasis. New England Journal of Medicine, 1995;332(9):581-589. https://doi.org/10.1056/NEJM199503023320907
[6] Pandey S, Tripathi P, Gupta A, et al. A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine. Drug Delivery and Translational Research, 2022;12:1541-1555. https://doi.org/10.1007/s13346-021-01059-5
[7] Fradin MS, Ellis CN and Voorhees JJ. Efficacy of cyclosporin A in psoriasis: a summary of the United States’ experience. British Journal of Dermatology, 1990;122(s36):21-25. https://doi.org/10.1111/j.1365-2133.1990.tb02878.x
[8] Tedesco D and Haragsim L. Cyclosporine: a review. Journal of Transplantation, 2012;2012. https://doi.org/10.1155/2012/230386
[9] Guada M, Sebastián V, Irusta S, et al. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity. International Journal of Nanomedicine, 2015;6541-6553. https://doi.org/10.2147/IJN.S90849
[10] Essaghraoui A, Belfkira A, Hamdaoui B, et al. Improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles. Nanomaterials, 2019;9(9):1204. https://doi.org/10.3390/nano9091204
[11] Jain S, Mittal A and Jain AK. Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. Current Nanoscience, 2011;7(4):524-530. https://doi.org/10.2174/157341311796196835
[12] Boinpally RR, Zhou SL, Devraj G, et al. Iontophoresis of lecithin vesicles of cyclosporin A. International Journal of Pharmaceutics, 2004;274(1-2):185-190. https://doi.org/10.1016/j.ijpharm.2004.01.016
[13] Liu H, Li S, Wang Y, et al. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. International Journal of Pharmaceutics, 2006;311(1-2):182-186. https://doi.org/10.1016/j.ijpharm.2005.12.029
[14] Lopes LB, Collett JH and Bentley MVLB. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. European Journal of Pharmaceutics and Biopharmaceutics, 2005;60(1):25-30. https://doi.org/10.1016/j.ejpb.2004.12.003
[15] Arora R, Katiyar SS, Kushwah V, et al. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opinion on Drug Delivery, 2017;14(2):165-177. https://doi.org/10.1080/17425247.2017.1264386
[16] Jeong HR, Kim JY, Kim SN, et al. Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. European Journal of Pharmaceutics and Biopharmaceutics, 2018;127:237-243. https://doi.org/10.1016/j.ejpb.2018.02.014
[17] Walunj M, Doppalapudi S, Bulbake U, et al. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. Journal of Liposome Research, 2020;30(1):68-79. https://doi.org/10.1080/08982104.2019.1593449
[18] Benigni M, Pescina S, Grimaudo MA, et al. Development of microemulsions of suitable viscosity for cyclosporine skin delivery. International Journal of Pharmaceutics, 2018;545(1-2):197-205. https://doi.org/10.1016/j.ijpharm.2018.04.049
[19] Prasad V, Kumar N and Mishra PR. Amphiphilic gels as a potential carrier for topical drug delivery. Drug Delivery, 2007;14(2):75-85. https://doi.org/10.1080/10717540600642431
[20] Bhardwaj P, Tripathi P, Gupta R, et al. Niosomes: a review on niosomal research in the last decade. Journal of Drug Delivery Science and Technology, 2020;56:101581. https://doi.org/10.1016/j.jddst.2020.101581
[21] Abdelbary AA and AbouGhaly MHH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. International Journal of Pharmaceutics, 2015;485(1-2):235-243. https://doi.org/10.1016/j.ijpharm.2015.03.020
[22] Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, et al. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo–in vivo evaluation study. International Journal of Nanomedicine, 2018;13:1059-1079. https://doi.org/10.2147/IJN.S156412
[23] Moghddam SRM, Ahad A, Aqil M, et al. Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Materials Science and Engineering: C, 2016;69:789-797. https://doi.org/10.1016/j.msec.2016.07.043
[24] Zhu B, Jing M, Yu Q, et al. Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 2022;39(3):460-471. https://doi.org/10.5114/ada.2021.108445
[25] Pandey SS, Shah KM, Maulvi FA, et al. Topical delivery of cyclosporine loaded tailored niosomal nanocarriers for improved skin penetration and deposition in psoriasis: Optimization, ex vivo and animal studies. Journal of Drug Delivery Science and Technology, 2021;63:102441. https://doi.org/10.1016/j.jddst.2021.102441
[26] Agarwal R, Katare OP and Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. International Journal of Pharmaceutics, 2001;228(1-2):43-52. https://doi.org/10.1016/S0378-5173(01)00810-9
[27] Lopes LB, Lopes JLC, Oliveira DCR, et al. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2006;63(2):146-155. https://doi.org/10.1016/j.ejpb.2006.02.003
[28] Ghate VM, Kodoth AK, Shah A, et al. Colloidal nanostructured lipid carriers of pentoxifylline produced by microwave irradiation ameliorates imiquimod-induced psoriasis in mice. Colloids and Surfaces B: Biointerfaces, 2019;181:389-399. https://doi.org/10.1016/j.colsurfb.2019.05.074
[29] Radhi AA. Benazepril hydrochloride loaded niosomal formulation for oral delivery: Formulation and characterization. International Journal of Applied Pharmaceutics, 2018;10:66-70. http://dx.doi.org/10.22159/ijap.2018v10i5.27564
[30] Yeo LK, Chaw CS and Elkordy AA. The effects of hydration parameters and co-surfactants on methylene blue-loaded niosomes prepared by the thin film hydration method. Pharmaceuticals, 2019;12(2):46. https://doi.org/10.3390/ph12020046
[31] Hao Y, Zhao F, Li N, et al. Studies on a high encapsulation of colchicine by a niosome system. International Journal of Pharmaceutics, 2002;244(1-2):73-80. https://doi.org/10.1016/S0378-5173(02)00301-0
[32] Aboul-Einien MH, Kandil SM, Abdou EM, et al. Ascorbic acid derivative-loaded modified aspasomes: formulation, in vitro, ex vivo and clinical evaluation for melasma treatment. Journal of Liposome Research, 2020;30(1):54-67. https://doi.org/10.1080/08982104.2019.1585448
[33] Priya S, Koland M and Suchetha KN. Formulation and characterization of ropinirole hydrochloride loaded solid lipid nanoparticles. International Journal of Pharmacy and Pharmaceutical Sciences, 2015;7(9):85-89.
[34] Zainol S, Basri M, Basri HB, et al. Formulation optimization of a palm-based nanoemulsion system containing levodopa. International Journal of Molecular Sciences, 2012;13(10):13049-13064. https://doi.org/10.3390/ijms131013049
[35] Pagar K and Vavia P. Rivastigmine-loaded L-lactide-depsipeptide polymeric nanoparticles: decisive formulation variable optimization. Scientia Pharmaceutica, 2013;81(3):865-888. https://doi.org/10.3797/scipharm.1211-20
[36] Manosroi A, Wongtrakul P, Manosroi J, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids and Surfaces B: Biointerfaces, 2003;30(1-2):129-138. https://doi.org/10.1016/S0927-7765(03)00080-8
[37] Aghajani A, Kazemi T, Enayatifard R, et al. Investigating the skin penetration and wound healing properties of niosomal pentoxifylline cream. European Journal of Pharmaceutical Sciences, 2020;151:105434. https://doi.org/10.1016/j.ejps.2020.105434
[38] Verma DD, Verma S, Blume G, et al. Particle size of liposomes influences dermal delivery of substances into skin. International Journal of Pharmaceutics, 2003;258(1-2):141-151. https://doi.org/10.1016/S0378-5173(03)00183-2
[39] Shahiwala A and Misra A. Studies in topical application of niosomally entrapped nimesulide. Journal of Pharmacy & Pharmaceutical Sciences, 2002;5(3):220-225.
Copyright © 2023 Peeyush Bhardwaj, Purnima Tripathi, Sonia Pandey, Deepti Chaurasia, Purushottam Ramchandra Patil
Publishing time:2023-10-25
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location